Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 485 DKK 1.57%
Market Cap: 98.3B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genmab A/S
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Current Portion of Long-Term Debt
kr94m
CAGR 3-Years
17%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Current Portion of Long-Term Debt
kr15.9m
CAGR 3-Years
1%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Current Portion of Long-Term Debt
€27.7m
CAGR 3-Years
60%
CAGR 5-Years
39%
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Current Portion of Long-Term Debt
kr41.9m
CAGR 3-Years
-68%
CAGR 5-Years
21%
CAGR 10-Years
17%
Bioporto A/S
CSE:BIOPOR
Current Portion of Long-Term Debt
kr2.2m
CAGR 3-Years
8%
CAGR 5-Years
-5%
CAGR 10-Years
60%
Saniona AB
STO:SANION
Current Portion of Long-Term Debt
kr4.9m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Genmab A/S
Glance View

Market Cap
94.2B DKK
Industry
Biotechnology
Economic Moat
Narrow

In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.

GMAB Intrinsic Value
2 682.76 DKK
Undervaluation 45%
Intrinsic Value
Price

See Also

What is Genmab A/S's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
94m DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Current Portion of Long-Term Debt amounts to 94m DKK.

What is Genmab A/S's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
25%

Over the last year, the Current Portion of Long-Term Debt growth was 15%. The average annual Current Portion of Long-Term Debt growth rates for Genmab A/S have been 17% over the past three years , 25% over the past five years .

Back to Top